Skip to main content

Table 3 Viral titers at V1 and V2 (log[x + 1]) in respective groups

From: Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials

Population Treatment Number of virus events Visit Virus titer (median (25%; 75% percentile) Significance (Wilcoxon Signed Rank Test) Reduction in viral titers (difference V1-V2) (median (25%; 75% percentile) Significant difference between carrageenan and placebo (Mann- Whitney U- test)
ITT Verum (n = 116) 154 V1 4.64 (3.41;6.57)    p = 0.022
  Verum (n = 116) 154 V2 3.61 (0;4.97) p < 0.001 −2.2 (−3.47;-0.26)  
  Placebo (n = 120) 163 V1 4.49 (3.24;6.3)    
  Placebo (n = 120) 163 V2 3.82 (0;4.85) p < 0.001 −1.14 (−3.31;0.31)  
PP Verum (n = 87) 115 V1 4.66 (3.4;6.54)    p = 0.044
  Verum (n = 87) 115 V2 3.63 (0;4.83) p < 0.001 −2.25 (−3.47;-0.57)  
  Placebo (n = 87) 113 V1 4.99 (3.35;6.49)    
  Placebo (n = 87) 113 V2 3.98 (2.24;4.89) p < 0.001 −1.2 (−3.24;0.21)